Eliem Therapeutics Shares Fall On Lower Back Pain Trial Setback
- Eliem Therapeutics Inc has reported results from its Phase 2a trial investigating ETX-810 for lumbosacral radicular pain (LSRP).
- In the study, ETX-810 did not achieve statistically significant separation from placebo on the trial's primary endpoint, which assessed the change from baseline to week 4 in the weekly average of the daily pain score.
- This result is consistent with the lack of separation from placebo observed in the Phase 2a clinical trial in diabetic peripheral neuropathic pain, as reported in April.
- Therefore, the company has elected to discontinue further development of ETX-810.
- The company recently updated that its capital is sufficient to fund key pipeline catalysts and operations until mid-2024.
- With the discontinuation of ETX-810, the company anticipates that its cash runway will extend beyond that time.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.